Skip to main
APYX
APYX logo

APYX Stock Forecast & Price Target

APYX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apyx Medical Corp reported a notable 31.4% year-over-year increase in total revenue for the third quarter of 2023, reaching $12.0 million, with the Advanced Energy segment driving a substantial 38.9% increase to $9.8 million. The company also experienced an improvement in gross margins, which rose 345 basis points year-over-year to 66.6%, indicating enhanced profitability amidst rising demand for its innovative products. Furthermore, Apyx has raised its OEM revenue guidance to $8.5 million and anticipates stronger growth in the second half of 2024 compared to the first half, suggesting a positive trajectory for the company's financial performance.

Bears say

Apyx Medical Corp's financial outlook has deteriorated due to a series of downward revisions in key metrics, including a reduction in 2023 revenue guidance to approximately $53 million, which is below consensus estimates. The company's gross margin forecast was also lowered to 66%, down from a previous range of 66.5% to 67.5%, reflecting a shortfall against market expectations and operational challenges. Furthermore, Apyx reported a non-GAAP loss per share of ($0.13), which was a significant miss of 44.4% compared to consensus, highlighting ongoing issues with sales execution and the impact of external economic factors on performance.

APYX has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apyx Medical Corp (APYX) Forecast

Analysts have given APYX a Buy based on their latest research and market trends.

According to 4 analysts, APYX has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apyx Medical Corp (APYX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.